» Articles » PMID: 8044824

Persistent Augmentation of Natural-killer- and T-cell-mediated Cytotoxicity in Peripheral Blood Mononuclear Cells Pulsed in Vitro with High-dose Recombinant Interleukin-2 Prior to Culturing with a Low Maintenance Dose

Overview
Date 1994 Jul 1
PMID 8044824
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

The toxicity of high-dose recombinant interleukin-2 (rIL-2) treatment limits its use in tumour therapies. This paper describes in vitro studies of whether a single, peak rIL-2 dose, followed by low maintenance doses, could enhance the cytotoxic potential of peripheral blood mononuclear cells (PBMC) without inducing a significant sustained release of secondary cytokines, known to contribute to undesirable side-effects of therapy. Pre-pulsing of PBMC with high-dose rIL-2 (16,000 IU/ml for 30 min), followed by low-dose (5 IU/ml) maintenance culturing, was found to induce persistent augmentation of cytotoxic activity towards natural-killer(NK)-sensitive and -insensitive tumour targets, as well as increased T-cell-mediated target cell killing. Under these conditions the level of killing was as high as that achieved by higher maintenance doses (20-100 IU/ml). Although not reflected by overexpression of cell surface markers, enhanced activation of cytotoxic capacities by high-dose pre-pulsing remained clearly apparent for at least 12 days of culture. Increased secondary cytokine production (tumour necrosis factor, interleukin-6 and interferon gamma) was only evident during the first 24-72 h after pulsing, and not at later stages of culturing at the low maintenance dose of 5 IU rIL-2/ml. These results may warrant a human phase-1 B study to investigate the in vivo effect of high-dose prepulsing, followed by low-dose maintenance.

Citing Articles

Possible stimulation of anti-tumor immunity using repeated cold stress: a hypothesis.

Shevchuk N, Radoja S Infect Agent Cancer. 2007; 2:20.

PMID: 17999770 PMC: 2211456. DOI: 10.1186/1750-9378-2-20.

References
1.
Rosenberg S, Lotze M, Yang J, Aebersold P, Linehan W, Seipp C . Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg. 1989; 210(4):474-84; discussion 484-5. PMC: 1357927. DOI: 10.1097/00000658-198910000-00008. View

2.
Caligiuri M, Zmuidzinas A, Manley T, Levine H, Smith K, Ritz J . Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med. 1990; 171(5):1509-26. PMC: 2187895. DOI: 10.1084/jem.171.5.1509. View

3.
KONRAD M, Hemstreet G, Hersh E, Mansell P, Mertelsmann R, Kolitz J . Pharmacokinetics of recombinant interleukin 2 in humans. Cancer Res. 1990; 50(7):2009-17. View

4.
Parkinson D . Interleukin-2: further progress through greater understanding. J Natl Cancer Inst. 1990; 82(17):1374-6. DOI: 10.1093/jnci/82.17.1374. View

5.
Talmadge J, Phillips H, Schindler J, Tribble H, Pennington R . Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease. Cancer Res. 1987; 47(21):5725-32. View